Recently, we agreed with a fellow investor that it is hard to rifle-shot a winning neurotech, especially a BCI opportunity. There are so many unknowns in the world of brain tech. Among them are: 1) modalities (ultrasound vs EEG vs ...); 2) delivery routes - non-invasive, minimally-invasive, invasive; 3) mechanisms of actions? And I'm not even talking about GTM, applications, regulations, etc.
So, investors have to keep their eyes open, support various approaches, and invest across spectrums of modalities and delivery mechanisms.
In this note, I tried to describe how I think about a successful/fundable neurotech/BCI startup without being too restrictive. It's the first attempt and not cut in stone.
I'd appreciate feedback and your ideas; please ping me here or privately and do let me know if I said anything funny!
I'd love a public discussion, as it's useful for founders. Thomas Oxley, Matt Angle, James Dacombe, Matthieu Vallin, Joao Barbosa da Silva, Katherine Jones, Jordi Parramon, Dorian Haci, PhD, Sourav Kole, 🧠 Sam Hosovsky, Laura K., Gus Domel, PhD, Ben Woodington, Mike Annunziata
Kudos to Lewis Bates, Yildiz Dilara Parry, Sophie Valentine, and Lars O. for helping me to structure the initial brain dump, make it readable, and for asking hard questions.
📖 Subscribe to NeuroTechX Content Lab for more long-reads - https://lnkd.in/euNZRCAF
📩 Subscribe for a monthly neuro newsletter by me - https://lnkd.in/eT5gy-5Q
https://lnkd.in/ehMP_6dG
#bci #braincomputerinterface #brain #venturecapital #deeptech #neurotech #neurotechnology #neuroscience #implants
https://bit.ly/3wEYGeM